FDA Approves Eli Lilly's Once-a-Week Insulin Injection for Type 2 Diabetes Treatment
The treatment, based on trials of more than 3,400 adults, may reduce annual injections by more than 300, Lilly said.
- On Thursday, September 24, 2026, the U.S. Food and Drug Administration approved Eli Lilly and Company's Onswik , a once-weekly basal insulin for adults with type 2 diabetes.
- The regulatory approval follows the QWINT clinical trial program, which evaluated Onswik's safety and efficacy in over 3,400 adults across four global registration studies beginning in 2022.
- Onswik is designed to deliver steady basal insulin levels over seven days, reducing annual injections by more than 300 compared with daily basal insulin alternatives.
- The drug will be available in the coming months as a pre-filled Onswik KwikPen in two concentrations—500 units/mL and 1,000 units/mL—for use with diet and exercise.
- Previous clearances for Onswik include Europe, Mexico, and Japan; however, Eli Lilly cautions the drug should not be used by people with type 1 diabetes due to increased severe hypoglycemia risk.
14 Articles
14 Articles
US FDA approves Lilly’s once-weekly insulin injection for type 2 diabetes - Regional Media News
Sept 24 (Reuters) - The US Food and Drug Administration has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering patients an alternative to daily long-acting insulin injections. Here are some details: • Onswik, chemically [...]
FDA approves Onswik, a once-weekly basal insulin, for adults with type 2 diabetes
The FDA has approved a once-weekly basal insulin to control glucose levels for adults with type 2 diabetes, Eli Lilly announced.Insulin efsitora alfa-gobe (Onswik, Lilly) is a therapy that can deliver steady levels of basal insulin to adults with type 2 diabetes for 7 days. The FDA approved insulin efsitora alfa-gobe for use alongside diet and exercise to help maintain glycemic control.
FDA approves Eli Lilly's once-a-week insulin injection for type 2 diabetes treatment
Adults with type 2 diabetes will have a new alternative to daily insulin injections now that the U.S. Food and Drug Administration (FDA) approved a new once-a-week insulin injection.
US FDA approves Lilly’s once-weekly insulin injection for type 2 diabetes
Sept 24 (Reuters) - The US Food and Drug Administration has approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering patients an alternative to daily long-acting insulin injecti...
Coverage Details
Bias Distribution
- 73% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
